Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

Background & Aims: Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic respons...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ana Garcia Garcia de Paredes, Càndid Villanueva, Carolina Blanco, Joan Genescà, Nicolo Manicardi, Juan Carlos Garcia-Pagan, Jose Luis Calleja, Carlos Aracil, Rosa M. Morillas, Maria Poca, Beatriz Peñas, Salvador Augustin, Juan G. Abraldes, Eldimar Alvarado, Félix Royo, Maria Laura Garcia-Bermejo, Juan Manuel Falcon-Perez, Rafael Bañares, Jaime Bosch, Jordi Gracia-Sancho, Agustin Albillos
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Ascites beta-blockers cirrhosis microRNA portal hypertension Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/59ab79c9a0de4e2da9fed5699a961c6b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

Ejemplares similares